Literature DB >> 9426462

Gene expression by atypical recombinant ovine adenovirus vectors during abortive infection of human and animal cells in vitro.

A Khatri1, Z Z Xu, G W Both.   

Abstract

An bovine adenovirus, which is phylogenetically distinct from the Mastadeno- and Aviadenoviruses, was used to construct recombinants in which reporter genes were expressed from the OAV major late, or human cytomegalovirus promoters. It was demonstrated by transgene expression that OAV could infect bovine nasal turbinate and rabbit kidney cells as well as a range of human cell types, including lung and foreskin fibroblasts as well as liver, prostate, breast, colon, and retinal lines. Some human lines, e.g., 293 and LNCaP were not detectably infected. Infection occurred even though OAV has a fiber protein with a unique cell binding domain and a penton protein that lacks the integrin-binding Arg-Gly-Asp motif which facilitates entry by human adenoviruses. Most cell lines showed little or no ill effect for several days after infection but a prominent cytopathic effect appeared in fibroblasts after 3-4 days. However, no viral DNA synthesis was detected and replication was abortive. Viral promoter activity during infection of nonpermissive cell types was assayed by RT-PCR. Early promoter activity was detectable in some, but not all cell types. In a liver and a colon carcinoma cell line, none of the promoters examined was significantly active, even when a higher multiplicity of infection was used. Major late promoter activity was not detectable in any cell type. The lack of DNA replication and MLP function suggests that a critical transition from early to late gene expression does not occur during abortive infection by OAV.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9426462     DOI: 10.1006/viro.1997.8861

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo.

Authors:  C Hofmann; P Löser; G Cichon; W Arnold; G W Both; M Strauss
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Cryoelectron microscopy map of Atadenovirus reveals cross-genus structural differences from human adenovirus.

Authors:  Radosav S Pantelic; Linda J Lockett; Rosalba Rothnagel; Ben Hankamer; Gerald W Both
Journal:  J Virol       Date:  2008-05-28       Impact factor: 5.103

3.  Induction of both cellular and humoral immunity following a rational prime-boost immunization regimen that incorporates recombinant ovine atadenovirus and fowlpox virus.

Authors:  Cara K Fraser; Kerrilyn R Diener; Erin L Lousberg; Gerald W Both; Larry Ward; Michael P Brown; John D Hayball
Journal:  Clin Vaccine Immunol       Date:  2010-09-01

4.  Mutational analysis of the avian adenovirus CELO, which provides a basis for gene delivery vectors.

Authors:  A I Michou; H Lehrmann; M Saltik; M Cotten
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

Review 5.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Authors:  Estrella Lopez-Gordo; Iva I Podgorski; Nicholas Downes; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

6.  Biology of ovine adenovirus infection of nonpermissive cells.

Authors:  Daniel Kümin; Christian Hofmann; Michael Rudolph; Gerald W Both; Peter Löser
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

7.  Construction, rescue, and characterization of vectors derived from ovine atadenovirus.

Authors:  Peter Löser; Christian Hofmann; Gerald W Both; Wolfgang Uckert; Moritz Hillgenberg
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 8.  Development of nonhuman adenoviruses as vaccine vectors.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Vaccine       Date:  2005-09-23       Impact factor: 3.641

Review 9.  Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs.

Authors:  Julio Alonso-Padilla; Tibor Papp; Győző L Kaján; Mária Benkő; Menzo Havenga; Angelique Lemckert; Balázs Harrach; Andrew H Baker
Journal:  Mol Ther       Date:  2015-10-19       Impact factor: 11.454

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.